References
- Cornely OA, Aversa F, Cook P, et al. Evaluating the role of prophylaxis in the management of invasive fungal infections in patients with hematologic malignancy. Eur J Haematol. 2011;87:289–301.
- Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. JCO. 2007;25:5471–5489.
- Ziakas PD, Kourbeti IS, Mylonakis E. Systemic antifungal prophylaxis after hematopoietic stem cell transplantation: a meta-analysis. Clin Ther. 2014;36:292–306.
- Bow EJ, Vanness DJ, Slavin M, et al. Systematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients. BMC Infect Dis. 2015;15:1–11.
- Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348–359.
- Tahami Monfared AA, O’Sullivan AK, Rotstein C, et al. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol. 2012;23:59–64.
- Kung H-C, Johnson MD, Drew RH, et al. Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology–oncology patients: a retrospective cohort study. Cancer Med. 2014;3:667–673.
- Collins CD, Ellis JJ, Kaul DR. Comparative cost-effectiveness of posaconazole versus fluconazole or itraconazole prophylaxis in patients with prolonged neutropenia. Am J Health Syst Pharm. 2008;65:2237–2243.
- Devanlay C, Tavernier-Tardy E, Bourmaud A, et al. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia. Biomed J. 2015;38:235–243.
- O’Sullivan AK, Pandya A, Papadopoulos G, et al. Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009;12:666–673.
- Heng S-C, Slavin MA, Al-Badriyeh D, et al. Pharmacoeconomic evaluation of fluconazole, posaconazole and voriconazole for antifungal prophylaxis in patients with acute myeloid leukaemia undergoing first consolidation chemotherapy. J Antimicrob Chemother. 2013;68:1669–1678.
- Stam WB, O’Sullivan AK, Rijnders B, et al. Economic evaluation of posaconazole vs. standard Azole prophylaxis in high risk neutropenic patients in the Netherlands. Eur J Haematol. 2008;81:467–474.
- Monfared AAT, O’Sullivan AK. Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive fungal infections in patients with prolonged neutropenia in Canada. Can J Infect Dis Med Microbiol. 2012;23:59–64.
- Jansen JP, O’Sullivan AK, Lugtenburg E, et al. Economic evaluation of posaconazole versus fluconazole prophylaxis in patients with graft-versus-host disease(GVHD) in the Netherlands. Ann Hematol. 2010;89:919–926.
- De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–1821.
- Robert CP, Casella G. Monte carlo statistical methods. 2nd ed. New York: Springer; 2004.
- O’Sullivan AK, Weinstein MC, Pandya A, et al. Cost-effectiveness of posaconazole versus fluconazole for prevention of invasive fungal infections in U.S. patients with graft-versus-host disease. Am J Health Syst Pharm. 2012;69:149–156.
- Bertz H, Drognitz K, Finke J. Analysis of the efficiency and costs of antifungal prophylaxis and mycological diagnostics in patients undergoing allogeneic haematopoietic cell transplantation: “real life” evaluation. Ann Hematol. 2016;95:457–463.